Pain reduction after percutaneous vertebroplasty for myeloma-associated vertebral fractures.
Simony A et al. Dan Med J. 2014 Dec;61(12):A4945.
Bone-targeted therapies for cancer patients and bone cell biology: where do we stand?
Berenson JR et al. Curr Opin Support Palliat Care. 2014 Dec;8(4):405-6. doi: 10.1097/SPC.0000000000000104.
The Role Of P2X Receptors In Bone Biology. Jorgensen NR et al. Curr Med Chem. 2014 Dec 14. [Epub ahead of print]. A joined role of canopy and reversal cells in bone remodeling – Lessons from glucocorticoid-induced osteoporosis. Jensen PR et al. Bone. 2014 Dec 10. pii: S8756-3282(14)00456-6. doi: 10.1016/j.bone.2014.12.004. [Epub ahead of print]. Multiple myeloma and chronic leukaemias in 2014: Improved…
Bortezomib-induced acute pancreatitis: Case report and review of the literature. Talamo G et al. J Oncol Pharm Pract. 2014 Dec 15. pii: 1078155214563813. [Epub ahead of print]. Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital. Teh BW et al. Support Care Cancer. 2014 Dec…
Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients: a retrospective study.
Oriol A et al. Hematology. 2014 Dec 10. [Epub ahead of print]
Ex Vivo-expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients. Szmania S et al. J Immunother. 2014 Nov 20. [Epub ahead of print]. Establishment of a Murine Graft-versus-Myeloma Model Using Allogeneic Stem Cell Transplantation. Binsfeld M et al. PLoS One. 2014 Nov 21;9(11):e113764. doi: 10.1371/journal.pone.0113764. eCollection 2014. Exploration for the multi-effect of cardamom in’s resistance to multiple myeloma. Zhihua…
Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy. Mathis S et al. Cytometry B Clin Cytom. 2014 Nov 17. doi: 10.1002/cyto.b.21200. [Epub ahead of print]. Clinical Course and Prognosis of Non-Secretory Multiple Myeloma. Chawla SS et al. Eur J Haematol. 2014 Nov 10. doi: 10.1111/ejh.12478. [Epub ahead of print]. The prognostic value…
Plasma cell leukemia. Ravinet A et al. Bull Cancer. 2014 Nov 1;101(11):1048-1058. A rare case of IGH/MYC and IGH/BCL2 double hit primary plasma cell leukemia. Kalff A et al. Haematologica. 2014 Nov 7. pii: haematol.2014.111385. [Epub ahead of print]. Solitary extramedullary plasmocytoma of the thyroid: a case report and histological approach to plasma cells infiltrate in the thyroid gland. Wilmars MM et…
Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma. Tolcher AW et al. Cancer Chemother Pharmacol. 2014 Nov 25. [Epub ahead of print]. Panobinostat: a review of trial results and future prospects in multiple myeloma. Libby EN et al. Expert Rev Hematol. 2014 Nov 20:1-10. [Epub ahead of print].…
Treatment of multiple myeloma bone disease: experimental and clinical data. Papamerkouriou YM et al. Expert Opin Biol Ther. 2014 Nov 12:1-18. [Epub ahead of print]. Bisphosphonates in multiple myeloma: a fractured consensus. Kumar SK. Leuk Lymphoma. 2014 Nov 5:1-2. [Epub ahead of print]. A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma. Berenson JR et al. Support Care…
The potential for a generally applicable mapping model between QLQ-C30 and SF-6D in patients with different cancers: a comparison of regression-based methods. Kontodimopoulos N. Qual Life Res. 2014 Nov 13. [Epub ahead of print]. Prevalence of monoclonal gammopathy in HIV patients in 2014. Genet P et al. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19649. doi: 10.7448/IAS.17.4.19649. eCollection 2014.…